Q-omics provides the consensus-scored FAM90A11P profile across patient tissues and cancer cell-line models. FAM90A11P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, FAM90A11P is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, FAM90A11P RNA expression shows 7,306 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CHOL, LUSC, and UVM as cancer lineages where FAM90A11P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM90A11P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM90A11P survival associations across molecular data types. FAM90A11P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM90A11P RNA expression–survival associations across cancer types. High FAM90A11P expression shows unfavorable associations in CHOL, ACC, SKCM, LUSC, CESC and THCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for FAM90A11P RNA expression.
This table summarizes FAM90A11P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM90A11P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM90A11P shows lower tumor expression in LUSC, UCEC and STAD. The LUSC box plot shows higher FAM90A11P RNA expression in normal versus tumor tissue (log2 FC = −0.015, t-test p = .029).
This table shows molecular features associated with FAM90A11P in patient tissues and cancer cell lines. In patient samples, FAM90A11P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
